Cell culture medium for human liver epithelial cell line
    52.
    发明授权
    Cell culture medium for human liver epithelial cell line 失效
    人肝上皮细胞系细胞培养液

    公开(公告)号:US5342777A

    公开(公告)日:1994-08-30

    申请号:US844873

    申请日:1992-03-03

    摘要: The present invention relates to cell medium developed to support long term multiplication and permanent establishment of a cell line of human liver epithelial cells. The medium may contain an effective cell growth promoting amount of calcium ions; an effective cell growth promoting amount of glucose; an effective amount of insulin to aid cells in glucose uptake; an effective cell growth promoting amount of hydrocortisone; an effective amount of epidermal growth factor to bind epidermal growth factor receptors on cells; an effective amount of transferrin to increase DNA synthesis in cells; an effective amount of cholera toxin to increase DNA synthesis in cells; an effective amount of triiodothyronine to increase DNA synthesis in cells; and an effective growth promoting amount of mammalian hormones and mitogenic factors, including lipoprotein, cholesterol, phospholipids and fatty acids.

    摘要翻译: 本发明涉及开发用于支持长期繁殖和永久建立人肝上皮细胞细胞系的细胞培养基。 介质可能含有有效的细胞生长促进量的钙离子; 有效的细胞生长促进量的葡萄糖; 有效量的胰岛素以帮助细胞摄取葡萄糖; 有效的细胞生长促进量的氢化可的松; 有效量的表皮生长因子结合细胞上的表皮生长因子受体; 有效量的转铁蛋白增加细胞中的DNA合成; 有效量的霍乱毒素以增加细胞中的DNA合成; 有效量的三碘甲状腺原氨酸增加细胞中的DNA合成; 以及哺乳动物激素和促有丝分裂因子的有效生长促进量,包括脂蛋白,胆固醇,磷脂和脂肪酸。

    POT1 ALTERNATIVE SPLICING VARIANTS
    59.
    发明申请
    POT1 ALTERNATIVE SPLICING VARIANTS 有权
    POT1替代性分离变量

    公开(公告)号:US20120016003A1

    公开(公告)日:2012-01-19

    申请号:US13027854

    申请日:2011-02-15

    摘要: The present invention provides methods and compositions for diagnosis and treatment of carcinomas with aberrant expression patterns of POT 1. The invention also provides methods of identifying compounds that may modulate the cellular expression of POT 1. The invention further provides methods for treating subjects suffering from or at risk of developing a colorectal carcinoma.

    摘要翻译: 本发明提供用于诊断和治疗POT1异常表达模式的癌症的方法和组合物。本发明还提供鉴定可调节POT1的细胞表达的化合物的方法。本发明还提供了治疗患有或 有发生结肠直肠癌的风险。

    INFLAMMATORY GENES AND MICRORNA-21 AS BIOMARKERS FOR COLON CANCER PROGNOSIS
    60.
    发明申请
    INFLAMMATORY GENES AND MICRORNA-21 AS BIOMARKERS FOR COLON CANCER PROGNOSIS 审中-公开
    炎症基因和MICRORNA-21作为结肠癌预后的生物标志物

    公开(公告)号:US20110183859A1

    公开(公告)日:2011-07-28

    申请号:US13121020

    申请日:2009-09-25

    IPC分类号: C40B30/00 C40B40/06

    CPC分类号: G01N33/57419

    摘要: Disclosed herein are methods for detecting a more aggressive form of a colon adenocarcinoma in a subject, thereby predicting the prognosis of the subject. The methods generally include determining an inflammatory gene expression signature in the colon adenocarcinoma and/or the adjacent non-cancerous tissue. In some embodiments, the inflammatory genes include, but are not limited to, PRG1, ANXA1, IL-17a, IL-23a FOXP3, HLA-DRA, IL-10, CD68 and IL-12a. In some embodiments, the method further includes detecting expression of microRNA-21 (miR-21) in the colon adenocarcinoma. Altered expression of one or more of the inflammatory genes or miR-21 indicates the prognosis of the subject. Also provided are arrays consisting essentially of probes specific for PRG1, ANXA1, IL-17a, IL-23a, FOXP3, HLA-DRA, IL-10, CD68, IL-12a and miR-21.

    摘要翻译: 本文公开了用于检测受试者中更积极形式的结肠腺癌的方法,从而预测受试者的预后。 所述方法通常包括确定结肠腺癌和/或相邻非癌组织中的炎症基因表达特征。 在一些实施方案中,炎症基因包括但不限于PRG1,ANXA1,IL-17a,IL-23a FOXP3,HLA-DRA,IL-10,CD68和IL-12a。 在一些实施方案中,该方法还包括检测结肠腺癌中的microRNA-21(miR-21)的表达。 一个或多个炎症基因或miR-21的改变表达表明受试者的预后。 还提供了基本上由PRG1,ANXA1,IL-17a,IL-23a,FOXP3,HLA-DRA,IL-10,CD68,IL-12a和miR-21特异性的探针组成的阵列。